FibroBiologics receives three Japanese patents for fibroblast therapy technology

FibroBiologics, Inc.

Japan Patent Office issued patents 7333272, 7386162, and 7387603, all invented by CEO Pete O'Heeron.
Patents cover methods enhancing fibroblast therapeutic activity, regenerative activity, and fibroblast-immune cell interaction.
Expands FibroBiologics' IP portfolio in Japan, a key cell therapy market.
Company is clinical-stage, focused on fibroblast-derived therapeutics for chronic diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.